Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

Stock Information for Ovid Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Ovid Therapeutics Inc.

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.